225 related articles for article (PubMed ID: 32187230)
1. Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.
Nowling TK; Rodgers J; Thiyagarajan T; Wolf B; Bruner E; Sundararaj K; Molano I; Gilkeson G
PLoS One; 2020; 15(3):e0230499. PubMed ID: 32187230
[TBL] [Abstract][Full Text] [Related]
2. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis.
Nowling TK; Mather AR; Thiyagarajan T; Hernández-Corbacho MJ; Powers TW; Jones EE; Snider AJ; Oates JC; Drake RR; Siskind LJ
J Am Soc Nephrol; 2015 Jun; 26(6):1402-13. PubMed ID: 25270066
[TBL] [Abstract][Full Text] [Related]
3. FLI1 Levels Impact CXCR3 Expression and Renal Infiltration of T Cells and Renal Glycosphingolipid Metabolism in the MRL/lpr Lupus Mouse Strain.
Sundararaj KP; Thiyagarajan T; Molano I; Basher F; Powers TW; Drake RR; Nowling TK
J Immunol; 2015 Dec; 195(12):5551-60. PubMed ID: 26538397
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase activity mediates IL-6 production by activated lupus-prone mesangial cells.
Sundararaj K; Rodgers JI; Marimuthu S; Siskind LJ; Bruner E; Nowling TK
Am J Physiol Renal Physiol; 2018 Apr; 314(4):F630-F642. PubMed ID: 29357434
[TBL] [Abstract][Full Text] [Related]
5. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
Shi Y; Yao W; Sun L; Li G; Liu H; Ding P; Hu W; Xu H
BMC Nephrol; 2019 Nov; 20(1):424. PubMed ID: 31752725
[TBL] [Abstract][Full Text] [Related]
6. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
Kadiombo AT; Maeshima A; Kayakabe K; Ikeuchi H; Sakairi T; Kaneko Y; Hiromura K; Nojima Y
Am J Physiol Renal Physiol; 2017 Feb; 312(2):F297-F304. PubMed ID: 27881396
[TBL] [Abstract][Full Text] [Related]
7. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.
Oates JC; Halushka PV; Hutchison FN; Ruiz P; Gilkeson GS
Am J Med Sci; 2011 Feb; 341(2):101-5. PubMed ID: 20924284
[TBL] [Abstract][Full Text] [Related]
8. The role of neuraminidase 1 (NEU1) in cytokine release by primary mouse mesangial cells and disease outcomes in murine lupus nephritis.
Rodgers J; Sundararaj K; Bruner E; Wolf B; Nowling TK
Autoimmunity; 2021 May; 54(3):163-175. PubMed ID: 33749450
[TBL] [Abstract][Full Text] [Related]
9. Proteomics-Based Identification of Potential Therapeutic Targets of Artesunate in a Lupus Nephritis MRL/lpr Mouse Model.
Wen Q; Wang C; Chen D; Luo N; Fan J; Zhou Y; Yu X; Chen W
J Proteome Res; 2024 Apr; 23(4):1150-1162. PubMed ID: 38394376
[TBL] [Abstract][Full Text] [Related]
10. The role of neuraminidase in TLR4-MAPK signalling and the release of cytokines by lupus serum-stimulated mesangial cells.
Sundararaj K; Rodgers J; Angel P; Wolf B; Nowling TK
Immunology; 2021 Apr; 162(4):418-433. PubMed ID: 33314123
[TBL] [Abstract][Full Text] [Related]
11. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
13. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
15. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice.
Iwata Y; Boström EA; Menke J; Rabacal WA; Morel L; Wada T; Kelley VR
J Immunol; 2012 May; 188(9):4568-80. PubMed ID: 22467656
[TBL] [Abstract][Full Text] [Related]
16. Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.
Menke J; Bork T; Kutska B; Byrne KT; Blanfeld M; Relle M; Kelley VR; Schwarting A
Kidney Int; 2011 Feb; 79(4):452-63. PubMed ID: 20980973
[TBL] [Abstract][Full Text] [Related]
17. Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation.
He J; Sun M; Tian S
Innate Immun; 2018 Jul; 24(5):307-315. PubMed ID: 29874961
[TBL] [Abstract][Full Text] [Related]
18. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis.
Wüthrich RP; Fan X; Ritthaler T; Sibalic V; Yu DJ; Loffing J; Kaissling B
Autoimmunity; 1998; 28(3):139-50. PubMed ID: 9867126
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
20. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
